Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.52 |
| ▸ | NOS2 | P35228 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 3/20 | 0.46 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29498353 | 1.00 | NOS3 (0.52) | NOS3NOS2MAOANISCHPKM | |
| SCHEMBL2226165 | 0.85 | NOS3 (0.45) | NOS3NOS2MAOANISCHPKM | |
| SCHEMBL30710409 | 0.82 | TDP1 (0.45) | NOS3NOS2MAOANISCHPKM | |
| SCHEMBL29010834 | 0.80 | NOS2 (0.46) | NOS3NOS2MAOAPKMRAD52 | |
| SCHEMBL13805616 | 0.79 | NOS3 (0.49) | NOS3NOS2MAOAPKMALDH1A1 | |
| SCHEMBL18044406 | 0.78 | NOS3 (0.56) | NOS3NOS2MAOAPKMRAD52 | |
| SCHEMBL1973786 | 0.78 | NOS3 (0.52) | NOS3NOS2MAOAPKMRAD52 | |
| SCHEMBL2796745 | 0.77 | PKM (0.57) | NOS3NOS2MAOAPKMRAD52 | |
| SCHEMBL29384557 | 0.77 | MAPK10 (0.55) | NOS3NOS2MAOAALDH1A1KDM4E | |
| SCHEMBL163051 | 0.77 | MAPK10 (0.55) | NOS3NOS2MAOAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114195713-B | Method for synthesizing dihydroisoquinoline by catalyzing selective dehydrogenation of tetrahydroisoquinoline | 广东众源药业有限公司 | 2023-11-17 | — | — | CN | disclosed |
| EP-4135698-A2 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | The Trustees of Indiana University (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20230047626-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | THE TRUSTEES OF INDIANA UNIVERSITY | 2023-02-16 | — | — | US | disclosed |
| US-20220142973-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | THE TRUSTEES OF INDIANA UNIVERSITY | 2022-05-12 | — | — | US | disclosed |
| CN-114195713-A | Method for synthesizing dihydroisoquinoline by catalyzing selective dehydrogenation of tetrahydroisoquinoline | 西安石油大学 | 2022-03-18 | — | — | CN | disclosed |
| WO-2021212010-A2 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2021-10-21 | — | — | WO | disclosed |
| US-10600975-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190157576-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2019-05-23 | — | — | US | disclosed |
| CN-108698997-A | Histone demethylase inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2018-10-23 | — | — | CN | disclosed |
| US-20130248832-A1 | Phosphorescent Materials | UNIVERSAL DISPLAY CORPORATION | 2013-09-26 | — | — | US | disclosed |
| EP-1487798-A4 | SUBSTITUTED TETRAHYDROISOQUINOLINES AS C5A RECEPTOR MODULATORS | NEUROGEN CORP (US) | 2005-07-13 | — | — | EP | disclosed |
| US-6916830-B2 | Substituted tetrahydroisoquinolines as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1487798-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES AS C5A RECEPTOR MODULATORS | Neurogen Corporation (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040204446-A1 | Nitrogen compounds such as N-(2-Fluoro-benzyl)-N-indan-2-yl-2-(3-methyl-2-o-tolyl-piperidin-1-yl) -acetamide, administered for prophylaxis arthritis, psoriasis, cardiovascular disorders, reperfusion injury or respiratory system disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2004-10-14 | — | — | US | disclosed |
| US-6777422-B2 | FOR TREATING A VARIETY OF INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NEUROGEN CORP. | 2004-08-17 | — | — | US | disclosed |
| US-20040006069-A1 | Substituted tetrahydroisoquinolines as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2004-01-08 | — | — | US | disclosed |
| WO-2003082828-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047626-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | TP53, EIF2AK2, POLI | NOS3 3977/4885NOS2 4037/4885MAOA 4493/4885 |
| US-20040006069-A1 | Substituted tetrahydroisoquinolines as C5a receptor modulators | C5AR1, C3AR1, C5AR2 | NOS3 3530/4885NOS2 3796/4885MAOA 856/4885 |
| US-20220142973-A1 | SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS | TP53, EIF2AK2, POLI | NOS3 3977/4885NOS2 4037/4885MAOA 4493/4885 |
| US-10600975-B2 | Organic electroluminescent materials and devices | TERT, OR10J3, RUVBL2 | NOS3 2512/4885NOS2 2481/4885MAOA 2592/4885 |
| US-20040204446-A1 | Nitrogen compounds such as N-(2-Fluoro-benzyl)-N-indan-2-yl-2-(3-methyl-2-o-tolyl-piperidin-1-yl) -acetamide, administered for prophylaxis arthritis, psoriasis, cardiovascular disorders, reperfusion injury or respiratory system disorders | C5AR1, C3AR1, C5AR2 | NOS3 133/4885NOS2 50/4885MAOA 546/4885 |
| US-20190157576-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | PIEZO1, ORAI2, PORCN | NOS3 3248/4885NOS2 2636/4885MAOA 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.